Type: Subsidiary
On the web: http://www.sunovion.com

Helping people breathe easy and sleep properly are the core of Sunovion (formerly Sepracor). The company focuses its drug development efforts in two main therapeutic categories: respiratory and central nervous system (CNS) disorders. Among its six marketed products are asthma drug Xopenex, insomnia therapy Lunesta, and chronic obstructive pulmonary disease (COPD) treatment Brovana. Sunovion markets its products to primary care physicians and some specialists in the US. It has licensed international development and commercialization rights for Lunesta to Eisai and GlaxoSmithKline. Sunovion is a subsidiary of Japanese firm Dainippon Sumitomo Pharma (DSP).

Officers:
Chairman and CEO: Saburo (Sam) Hamanaka
President, COO, and Director: Mark Iwicki
VP Corporate Planning and Corporate Communcations: Susan Adler

Competitors:
Cephalon
GlaxoSmithKline
Sanofi

© 2012 Hoover's, Inc. All rights reserved.